$6.32 -$0.03 (0.0%)

03:54 PM EDT on 07/18/19

Aurinia Pharmaceuticals (NASDAQ:AUPH)

CAPS Rating: 3 out of 5

Current Price $6.32 Mkt Cap $777.0M
Open $6.37 P/E Ratio 0.00
Prev. Close $6.32 Div. (Yield) $0.00 (0.0%)
Daily Range $6.30 - $6.37 Volume 32,325
52-Wk Range $6.00 - $7.84 Avg. Daily Vol.

Caps

How do you think NASDAQ:AUPH will perform against the market?

Add Stock to CAPS Watchlist

All Players

36 Outperform
4 Underperform
 

All-Star Players

11 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:AUPH Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

zzlangerhans (99.80)
Submitted October 06, 2016

Aurinia wins the comeback kid award after rebounding to 5.5 just six weeks after crashing to 1.73 on word of a substantial mortality imbalance favoring control in the AURA-LV phase IIb trial of voclosporin for lupus nephritis. Aurinia insists that… More

NASDAQ:AUPH VS S&P 500 (SPY)

NASDAQ:AUPH Summary

Fools bullish on NASDAQ:AUPH are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about AUPH.

Recs

0
Member Avatar john1tall (< 20) Submitted: 2/8/2018 10:48:58 AM : Outperform Start Price: $5.30 NASDAQ:AUPH Score: +6.64

AUPH is in stage III clinical trials with a drug to treat lupus. The first two trials showed tremendous promise for those who are presently suffering and have no real choice for treatment. What they do have to choose from is fraught with horrible side effects. The results are due by 2019 and if they are good AUPH could easily see $25+.

Recs

0
Member Avatar TMFEBCapital (92.42) Submitted: 7/12/2017 3:51:03 PM : Outperform Start Price: $6.26 NASDAQ:AUPH Score: -21.40

There aren't any FDA approved therapies for lupus nephritis (LN), and the patient population in the U.S. alone is up to 200k people. Current treatments fall short with single digit complete remission rates, but this company's drug - voclosporin -- delivered almost 50% rates in phase 2. A phase 3 is underway, and if successful, could result in this becoming a 9-figure (plus) drug.

Recs

0
Member Avatar mmr23 (< 20) Submitted: 3/7/2017 12:33:58 PM : Underperform Start Price: $6.82 NASDAQ:AUPH Score: +33.14

Article Here's Why Aurinia Pharmaceuticals Stock Is Soaring Today should also mention S-8 filed 3/3 to register 6.8 m shares
Should bring down the price in short term

Leaderboard

Find the members with the highest scoring picks in AUPH.

Score Leader

jack0071

jack0071 (71.61) Score: +163.58

The Score Leader is the player with the highest score across all their picks in AUPH.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
jack0071 71.61 12/28/2016 Outperform 5Y $2.14 +195.33% +31.75% +163.58 0 Comment
hayrettin 70.64 1/24/2017 Outperform 5Y $3.00 +110.67% +31.09% +79.57 0 Comment
shredlee 73.24 2/15/2017 Outperform 1Y $3.58 +76.54% +27.54% +48.99 0 Comment
eyezie1 < 20 11/21/2016 Outperform 5Y $3.58 +76.50% +35.97% +40.53 0 Comment
mmr23 < 20 3/7/2017 Underperform NS $6.82 -7.33% +25.81% +33.14 1 Comment
PayrollGeek < 20 8/20/2018 Outperform 5Y $5.29 +19.44% +4.43% +15.01 0 Comment
NextGenStock < 20 8/14/2018 Outperform 5Y $5.26 +20.15% +5.51% +14.64 0 Comment
t0bes < 20 11/16/2016 Outperform 5Y $4.23 +49.41% +37.19% +12.22 0 Comment
Doppelganger 35.83 10/10/2016 Underperform 5Y $4.90 +28.98% +38.10% +9.12 0 Comment
KiLleRBLT < 20 2/8/2018 Outperform 1Y $5.26 +20.15% +12.70% +7.45 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AUPH.

Advertisement